RxDoctor Payments Data

Nicole May

Family · Denham Springs, LANPI 1205338548

Payments from drug & device makers

$2,819in general payments, 2019–2025

Across 88 payments — averaging $32.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kestra Medical Technology Services, Inc.$943
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$567
  • AstraZeneca$457
  • Abbott$224
  • Biotronik Inc.$155
  • E.r. Squibb & Sons, L.L.C.$112
  • plus $361 from 7 others

What the payments were for

  • Food & beverage$2,62193%
  • Education$1987%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,819 in reported general payments places this provider in the 80th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$29,877
Medicare patients
225
Services billed
380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban620$518,488
EntrestoSacubitril/Valsartan439$383,997
FarxigaDapagliflozin Propanediol190$160,280
OzempicSemaglutide63$58,160
XareltoRivaroxaban64$52,058
WegovySemaglutide36$50,143
JardianceEmpagliflozin46$41,518
Repatha SureclickEvolocumab57$32,260
MounjaroTirzepatide15$17,491
DapagliflozinDapagliflozin Propanediol17$10,742
Ranolazine ErRanolazine96$8,045
Prasugrel Hcl50$7,091
Metoprolol Succinate553$6,902
Flecainide Acetate147$5,397
Amiodarone Hcl228$3,759

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$50$383,997439 claims
AstraZenecaFarxiga$457$160,280190 claims
Novo NordiskOzempic, Wegovy$106$108,30299 claims
Lilly USA, LLCMounjaro$24$17,49115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,610 family providers in Louisiana.

Other family in Denham Springs

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →